New drug combo aims to shrink spleens and ease symptoms in myelofibrosis patients
Disease control
Recruiting now
This study tests whether adding navtemadlin to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis who didn't get enough benefit from ruxolitinib. About 600 adults with high- or intermediate-risk myelofibrosis will take part. The goal i…
Phase: PHASE3 • Sponsor: Kartos Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC